Mereo BioPharma Group plc

For the period ended Dec 31, 2023. Filed Mar 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 27, 2024

MREO$0.30+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated balance sheets

	Year ended December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$57,421	$68,182
Prepaid expenses and other current assets	5,156	5,446
Research and development incentives receivables	1,183	1,569
Total current assets	63,760	75,197
Property and equipment, net	405	551
Operating lease right-of-use assets	1,245	1,665
Intangible assets	1,089	—
Total assets	$66,499	$77,413
Liabilities
Current liabilities:
Accounts payable	$2,346	$3,492
Accrued expenses	5,467	5,436
Convertible loan notes – current	—	13,326
Warrant liabilities – current	—	486
Operating lease liabilities – current	652	564
Other current liabilities	1,021	1,071
Total current liabilities	9,486	24,375
Convertible loan notes – non current	4,394	—
Warrant liabilities – non current	412	157
Operating lease liabilities – non current	906	1,479
Other non-current liabilities	764	—
Total liabilities	15,962	26,011
Commitments and contingencies (note 19)
Shareholders’ Equity
Ordinary shares, par value £0.003 per share; 701,217,089 shares issued at December 31, 2023 (2022: 624,928,519).	2,775	2,478
Treasury shares	(1,230)	(1,335)
Additional paid-in capital	486,107	476,521
Accumulated deficit	(419,630)	(404,575)
Accumulated other comprehensive loss	(17,485)	(21,687)
Total shareholders’ equity	50,537	51,402
Total liabilities and shareholders’ equity	$66,499	$77,413

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.